Consequently, disruption of FFA2 signaling has been implicated in several inflammatory and metabolic diseases such as ulcerative colitis, obesity, and diabetes, leading to the development of numerous non-lipid synthetic agonists and antagonists targeting FFA28. This evidence concerns the gene FFAR2 and metabolic disease.